Secretin - Innovate Biopharmaceuticals

Drug Profile

Secretin - Innovate Biopharmaceuticals

Alternative Names: INN-329; RG 1068; SecreFlo

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Repligen
  • Developer Repligen Corporation
  • Class Antipsychotics; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
  • Mechanism of Action Emission-computed tomography enhancers; Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic disorders
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Pancreatic disorders
  • No development reported Obsessive-compulsive disorders; Pancreatic cancer
  • Discontinued Autistic disorder; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-0 development in Pancreatic-cancer(Diagnosis) in USA (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 07 Jan 2015 No development reported - Phase-III for Pancreatic disorders (Diagnosis) and Diagnostic imaging in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top